Related Experiment Video

Updated: May 30, 2026

Implantation of Left Ventricular Assist Device (LVAD) in Juvenile Landrace Swine: A LVAD Implantation Model of Pediatric Heart Failure
05:18

Implantation of Left Ventricular Assist Device (LVAD) in Juvenile Landrace Swine: A LVAD Implantation Model of Pediatric Heart Failure

Published on: January 16, 2026

Role of β-blocker therapy in pediatric heart failure

Akash R Patel1, Robert E Shaddy

  • 1The Children's Hospital of Philadelphia, Department of Cardiology, 34th & Civic Center Boulevard, Philadelphia, PA 19104, USA Tel.: +1 215 590 3548.

Pediatric Health
|July 30, 2011
PubMed

Insights

Beta-blocker therapy shows promise for pediatric heart failure, though more research is needed. Understanding disease mechanisms and genetic factors will refine treatment for better outcomes in children.

Area of Science:

  • Pediatric Cardiology
  • Cardiovascular Research
  • Pharmacology

Background:

  • Pediatric heart failure is a growing concern due to cardiomyopathies and improved survival in congenital heart disease.
  • Adult heart failure treatment has advanced significantly, particularly with beta-blocker therapy.
  • Beta-blocker efficacy in pediatric heart failure is less established, with limited studies and small sample sizes.

Purpose of the Study:

  • To review the current understanding of beta-blocker therapy in pediatric heart failure.
  • To highlight challenges in studying beta-blocker efficacy in children.
  • To emphasize the need for further research into disease mechanisms and patient-specific therapies.

Main Methods:

  • Literature review of pediatric heart failure and beta-blocker therapy.
  • Analysis of challenges in pediatric clinical trials.
  • Discussion of molecular and genetic factors influencing treatment response.

Main Results:

  • Beta-blocker therapy has shown significant benefits in adult heart failure.
  • Evidence for beta-blockers in pediatric heart failure is less convincing and requires further investigation.
  • Heterogeneity and small sample sizes limit current pediatric studies.

Conclusions:

  • Further research into pediatric heart failure mechanisms is crucial.
  • Understanding age- and condition-specific differences will improve beta-blocker therapy.
  • Personalized, patient-specific therapeutic approaches are the future goal.

Related Concept Videos

Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antihypertensive Drugs: Types of β-Blockers01:28

Antihypertensive Drugs: Types of β-Blockers

β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and vasodilation. This widens airways and...
Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers01:25

Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers

β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but nonselective agent, paving the way...